IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v40y2022i1d10.1007_s40273-021-01105-7.html
   My bibliography  Save this article

Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management

Author

Listed:
  • Noman Paracha

    (F. Hoffmann-La Roche Ltd)

  • Pollyanna Hudson

    (Mtech Access Limited)

  • Stephen Mitchell

    (Mtech Access Limited)

  • C. Simone Sutherland

    (F. Hoffmann-La Roche Ltd)

Abstract

Background Spinal muscular atrophy (SMA) is a severe neuromuscular disease that is inherited in an autosomal recessive manner with an estimated incidence of 1 in 10,000 live births. The traditional classification of SMA includes five types (Types 0–4 SMA) based on patient age at disease onset and the highest motor milestone achieved. Spinal muscular atrophy leads to progressive muscle denervation, skeletal muscle atrophy and loss of motor function and ambulation, though phenotypes vary along a disease continuum. Regardless of disease severity, or access to treatment, a multidisciplinary approach to care is required to ease the burden of disease. To date, limited global data exist regarding the cost and resource use associated with SMA management. Objective We planned to perform a systematic literature review to identify studies on cost and healthcare resource use associated with SMA. Methods A comprehensive search was conducted in 2019 using several electronic databases in addition to supplementary sources and updated in 2021 in order to capture recently published studies. Electronic searches performed in Embase, MEDLINE, Evidence-Based Medicine Reviews and EconLit via the Ovid platform were supplemented by searches of the grey literature (reference lists, conference proceedings, global Health Technology Assessment body websites and other relevant sources). Study eligibility criteria were based on the population, interventions, comparators and outcomes (PICO) framework. Quality assessment of full-text publications was evaluated with reference to a published checklist. To accommodate heterogeneity across studies including countries, currencies, populations, time units and methods of reporting used, costs were reported in Euros in 2019. Results A total of 51 publications, comprising 49 unique studies of patients with SMA that met all eligibility criteria were included in the final selection. The publications comprised data from 14 countries and seven additional studies that reported multi-national data. Because of the heterogeneity between the different types of SMA, data were frequently reported separately for individuals with Type 1 or early-onset SMA and for Types 2, 3, and 4 SMA or later-onset SMA. Generally, direct medical costs and resource use were reported to be highest for patients with Type 1 SMA, decreasing incrementally for patients with Type 2 and Type 3 disease. Where cost categories were similar, direct costs were much lower in Europe than in the USA. Indirect costs were primarily associated with informal care, which was a substantial burden on patients and families in terms of both cost and time. Cost drivers were generally found to be dependent on SMA type. Conclusions Long-term robust studies are required to fully elucidate the economic burden of SMA. Considering that motor function can vary broadly, especially in Type 2 SMA, it would be beneficial to understand how costs and resource use are affected by different degrees of ambulation. Reporting data in terms of achieved motor function could also mitigate the challenges of comparing global data studies of small populations. Global, regional, and/or local data collection platforms and disease registry networks could play an important role in helping to address current data gaps.

Suggested Citation

  • Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland, 2022. "Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management," PharmacoEconomics, Springer, vol. 40(1), pages 11-38, April.
  • Handle: RePEc:spr:pharme:v:40:y:2022:i:1:d:10.1007_s40273-021-01105-7
    DOI: 10.1007/s40273-021-01105-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01105-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-021-01105-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Erik Landfeldt & Astrid Pechmann & Hugh J. McMillan & Hanns Lochmüller & Thomas Sejersen, 2021. "Costs of Illness of Spinal Muscular Atrophy: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 19(4), pages 501-520, July.
    2. Chris Sampson;Martina Garau, 2019. "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefing 002146, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Erik Landfeldt & Sophia Abner & Astrid Pechmann & Thomas Sejersen & Hugh J. McMillan & Hanns Lochmüller & Janbernd Kirschner, 2023. "Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review," PharmacoEconomics, Springer, vol. 41(3), pages 275-293, March.
    2. C. Simone Sutherland & Pollyanna Hudson & Stephen Mitchell & Noman Paracha, 2022. "Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers," PharmacoEconomics, Springer, vol. 40(1), pages 39-67, April.
    3. Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland, 2022. "Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)," PharmacoEconomics, Springer, vol. 40(1), pages 69-89, April.
    4. Amanda Whittal & Michela Meregaglia & Elena Nicod, 2021. "The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 14(5), pages 485-503, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:40:y:2022:i:1:d:10.1007_s40273-021-01105-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.